Herombopag Olamine in the Treatment of Thrombocytopenia After Chemotherapy

Inclusion Criteria: 1. Volunteer to participate in clinical research and sign informed consent; 2. Age ≥18 years; 3. Digestive system malignancy confirmed by histology or cytology; Having used oxaliplatin combined with fluorouracil for at least one cycle of 21-day chemotherapy regimen (CAPOX or SOX regimen), platelet index after chemotherapy: ≥25×109/L and ≤75×109/L; 4. At least 10 days between TPO, IL-11 or platelet transfusion; 5. ECOG 0 to 2 points; 6. Expected survival time \> 3 months; 7. Sufficient organ function for subsequent chemotherapy; 8. Women of reproductive age must be willing to use adequate contraception during the study of drug treatment. Exclusion Criteria: 1. Thrombocytopenia caused by non-tumor chemotherapy drugs occurred within 6 months before screening, including but not limited to EDTA-dependent pseudothrombocytopenia, hypersplenism, infection, and bleeding; 2. Have any hematological malignancies, including leukemia, myeloma, bone marrow proliferative diseases, lymphoma or bone marrow proliferative diseases; 3. Clinically significant acute or active bleeding within the week prior to screening; 4. Subject has medically known hereditary prethrombotic syndrome (e.g., factor V Leiden mutation, prothrombin G20210A mutation, or hereditary antithrombin III (ATIII) deficiency) 5. The subject has a history of major cardiovascular disease (e.g., congestive heart failure (New York Heart Association Class 3/ cardiac function), known arrhythmias (e.g., atrial fibrillation) that increase the risk of thromboembolic events, coronary stenting, angioplasty, or coronary artery bypass grafting); 6. Subjects had a history of arterial or venous thrombosis within 3 months before screening; 7. Use of a vitamin K antagonist (including low molecular weight heparin, factor Xa inhibitor, or thrombin inhibitor) within 7 days prior to screening; 8. The subject has a history of chronic platelet or hemorrhagic disorders, or thrombocytopenia from causes other than CIT (e.g., chronic liver disease or immune thrombocytopenic purpura); 9. TPO, IL-11 or platelet infusion were used within 10 days before enrollment; 10. Previous use of thrombopoietin receptor agonists (e.g., eltrobopag, romiestine, etc.) 11. Those who cannot be treated with oral drugs; 12. Allergic to hetrombopag or any excipient; 13. Those whose organ function could not tolerate further antitumor therapy as assessed by the investigator; This product is not recommended for use or discontinuation of treatment in patients who meet any of the following criteria for liver function ALT and AST \> 8 x ULN. ALT or AST\>5×ULN for 2 weeks; ALT or AST\>3xULN (total bilirubin \>2xULN or INR\>1.5); ALT or AST\>3×ULN with progressive fatigue, nausea, vomiting, right upper abdominal pain or tenderness, fever, rash, and/or eosinophilia (\>5%).